JBNI's Bioprin Demonstrates Anti-H. Pylori Results, A Known Cause of Stomach Ulcers

Warning: This document is intended for the scientific community only. Its sole purpose is to disclose test results concerning Bioprin, an herbal formula, as applied to H. Pylori.

SUMMARY: Due to a recent discovery by Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan that was published in the Lancet medical journal, JBNI has just released the anti-H. Pylori (a known cause of stomach ulcers) test report studying their herbal formula for nervous system health and comfort, Bioprin. This comes just after JBNI's last press release disclosing Bioprin's effectiveness on EMT-6, the equivalent of human metastatic breast cancer.

JBNI's Bioprin, their 100% herbal pain reliever, is reported to inhibit H. Pylori (a group I carcinogen for stomach cancer by the World Health Organization) in a clinical study by Food Products Laboratory, Inc. This study enlarges on the previous JBNI press release documenting Bioprin's anti-tumor effectiveness on EMT-6 (human metastatic breast cancer).

While only about 10,000 people die of stomach cancer annually, over 5,000,000 currently suffer from an ulcerated stomach lining, the main cause of stomach cancer. Over a lifetime, 1 in 10 will get a peptic ulcer which is, in turn, caused by H. Pylori.

Upon inhibition of H. Pylori, Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan demonstrated a two thirds lower likelihood of stomach cancer recurrence after initial treatment. To inhibit H. Pylori, Drs. Kato and Asaka used 30 milligrams of lansoprazole twice daily, 750 milligrams of amoxicillin twice daily, and 200 milligrams of clarithromycin twice a day for a week, Health Day news reported.

FPL's test of Bioprin against H. Pylori, FPL states, that Bioprin's testing "may indicate that H. Pylori is destroyed 100% on contact."

The summary impression states: "The inhibitor [Bioprin] is a highly turbid micro-granular natural herb extract. As the concentration increases, inhibition increases exponentially. This may indicate that H. Pylori is destroyed 100% on contact with the inhibitor. Very low inhibition by the clear supernatant of the formula supports this fact because the supernatant contains none or very little herbal extract. 10% supernatant results in 8mm inhibition zone. 10% whole Bioprin results in 30mm inhibition zone which is 10.56 times [greater] inhibition than the supernatant."

"MIC with well assays on TSA with 5% sheep blood" was the test method used. The spec as provided states, "well size: 6mm. Inhibition zones are the diameter including well."

When asked why Bioprin's anti-H. Pylori data was only recently published, Ken Case, JBNI's executive manager, stated, "JBNI wants to keep the message clear that Bioprin is first and foremost an all natural 100% herbal food supplement for nervous system calmness and vigor. It acts just as well to support the ease and comfort of muscles groups and vital organs that are under stress. Granted it tested high in anti-H. Pylori inhibition properties. Granted it shows anti-cancer properties reported by TSRA (Triple S Research Associates) in connection with Dana Farber Cancer Institute / Harvard Medical School. But JBNI's main focus for Bioprin is to safely and naturally deliver ease and comfort by supporting the body's own defense mechanisms."

Azim Walli, JBNI's general manager added, "Our entire line of herbal health formulas have multiple applications. But as with Bioprin, we want to focus on just one application so that the greatest number of people can experience the effectiveness of a purely herbal product. In fact, we don't even recommend that Bioprin be used in any other way than for aches and pains. We only share our test data with other scientists to educate on the potential of herbs."

Mr. Walli welcomes inquiry regarding distribution of JBNI's Bioprin at http://jbni.us/account . JBNI has been making the Bioprin formula broadly available to doctors and physicians for over 20 years. Bioprin has only been available directly to the public since July, 2008.

Proteomic Biomarkers In Drug Development

Biomarker (noun): Biomarkers are cellular, biochemical, or molecular alterations that are measurable in biological media such as human tissues, cells, or fluids. They indicate the presence of biological events or concerted events that are directly associated with a particular disease state.

Molecular Biomarkers (noun): Molecular biomarkers include proteins, carbohydrates, nucleic acids, and other compounds that provide insight into an individual’s health for screening risk factors, diagnosis, and prognosis. Molecular biomarkers are also extremely useful for drug discovery purposes.

Clinical Needs, Patient Perspective:
Am I at risk for cancer?
Is there anything I can do to alter the risk?
Do I have cancer?
Will my cancer respond to therapy?
Is my cancer responding to therapy?

Clinical Needs, Physician Perspective:
Identification of fingerprints associated with:

Prognosis at the time of diagnosis

Tumor responsiveness to therapy

Inter- and intratumor heterogeneity

Metastatic potential

Disease progression

CONTINUED: See Full PDF Document: Proteomic Biomarkers In Drug Development


Conclusions:
The study demonstrated efficacy of IND#70190 with overall improved performance scores and alleviation of asthma symptoms

Novel protein biomarkers for asthma and drug efficacy were identified

Drug effects are consistent with potent anti-inflammatory activity of IND#70190

Further clinical development and investigation of drug mechanism of action is warranted

Identification of Serum Biomarkers for Lung Cancer

Background: Symptoms of lung cancer (LC) often do not appear until the disease is advanced; only 15% of LC cases are discovered while the tumor is in the early stages of development. Carcinogen exposure, asthma and smoking have been determined to be risk factors for the development of LC. Early detection of LC will likely have a major impact on the natural history of the disease and facilitate curative treatment. The objective of this study was to apply multiplexed immunoassays to identify a panel of biomarkers for early detection of LC.

Methods: Normal (NO) serum controls (n = 30) from healthy volunteers and lung cancer patients (n = 30) were acquired from a commercial vendor. Baseline (pre-treatment) serum specimens from individuals with asthma (AST; n = 28) and lung cancer risk (LCR; n = 73) were available from clinical trials of two novel agents that are being developed by JBNI Inc. for the respective indications. Serum levels of 59 cytokines, growth factors and biologically active peptides were quantified using multiplexed immunoassays using the Luminex platform to identify biomarkers that are expressed in a significantly different manner in individuals with LC, LCR, or AST in comparison with NO subjects. Data were reduced using nearest neighbor cluster analysis with squared Euclidian distance to separate patients into groups across analytes with inter-pathology comparisons determined using Student’s t test.

Results: Multiple analytes showed highly significant differences (p < 0.0002) between LC and healthy controls as single indices of pathologic state. In addition we were able to differentiate AST from LC (p < 0.002) and LCR and LC (p < 0.0001) using a panel of thirteen markers in various combinations. Using multiplexed assays we found significant differences in biomarker levels in sera of LC compared to NO, in NO compared to AST and LC compared to AST samples. Our results support an extended multiplexed immunoassay-based analysis of serum biomarker profiles as supplementary tools for the diagnosis of pathologic and as an aid in the development of novel agents for prevention, early detection and treatment of LC.

Conclusions: We have identified a group of markers having high inter-pathology discrimination power that are capable of reliably differentiating AST and LC from control specimens. This panel remains to be validated in a larger set of specimens but we are confident that these measures will produce clinical assays capable of reliably diagnosing lung pathology.

A Proteomics Victory Over Cancer

04/14/07: Latest RCC Abstract

06/14/06: Our latest abstract

July 2005 our research in the battle against cancer won recognition in the scientific and pharmaceutical community to the extent that we have been presented on the cover of the July-August issue of " Cancer Genomics & Proteomics" , a journal published by the International Institute of Anticancer Research.

Novel natural products LP-01 and LP-02 developed by JBNI, were presented in cooperation with CTRC The Institute for Drug Development, San Antonio, TX at AACR-NCI-EORTC 2004: September 28-October 1, Geneva, Switzerland The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications was held in Geneva, Switzerland this past September. Our abstract on Serum Proteomic Biomarkers of a Natural Product in a Prospective Randomized Placebo-Controlled Clinical Trial in patients at risk for lung cancer was presented to the acclaim of the attendees.

In November of 2003, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery Biology, and Clinical Applications held in Boston, Massachusetts, an abstract entitled "Serum Biomarkers of Natural Product Therapy in Human Lung Cancer Xenograft Models" was presented, demonstrating the efficacy of our novel entities (LP-01 and LP-02) in high-risk lung cancer patients.

read our report on Novel serum biomarkers for renal cell carcinoma